跳至主要内容
临床试验/JPRN-UMIN000010002
JPRN-UMIN000010002已完成未知

Phase II study of pemetrexed maintenance with or without bevacizumab after a first line treatment chemotherapy with bevacizumab-carboplatin-pemetrexed in patients with advanced, metastatic or recurrent non-squamous non-small cell lung cancer - BPOP

Internal Medicine 2, Hamamatsu University School of Medicine.0 个研究点目标入组 110 人开始时间: 2013年2月8日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • interstitial lung disease history of hemoptysis myocardial infarction,unstable angina, stroke, transient ischemic attack significant vascular disease bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation hypertension or history of hypertensive crisis or encephalopathy; known CNS disease, except brain metastases treated with radiotherapy pregnancy abdominal fistula, or gastrointestinal perforation poorly controlled active ulcer known hypersensitivity to drug

研究者

发起方
Internal Medicine 2, Hamamatsu University School of Medicine.

相似试验